To clarify the changes in the TME of non-pCR patients following hormonal therapy, we performed scRNA-seq analysis on the primary tumor tissues and matched PDOs from nine HRLPC patients (Figure 1B), including two treatment-naïve samples (patient 01, 04), six castration-sensitive prostate cancer (CSPC) samples post-hormonal therapy (patient 02, 05, 06, 07, 08, 09), one amphicrine (AR+ and NE+) CRPC sample post-hormonal therapy (patient 03) (Figure 1C). This evidence concerns the gene AR and neoplasm.